All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
ASCO 2019 | Is immunotherapy toxicity associated with improved overall survival among older adults with MM?
Featured:
Ashley Elizabeth RoskoAt the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Ashley Elizabeth Rosko, Ohio State University Wexner Medical Center, discusses how immunotherapy toxicity is associated with improved overall survival among older adults with multiple myeloma. Dr. Rosko discusses how immunotherapy is becoming the standard of care for patients who are both newly diagnosed and in the relapsed setting; and how identifying toxicities that are unique for immunotherapy are particularly relevant for older adults. However, Dr. Rosko emphasizes that when utilizing these therapies which are both safe and effective, understanding the long term consequences need to be reevaluated.
Is immunotherapy toxicity associated with improved overall survival among older adults with MM?
Your opinion matters
HCPs, which of the following best characterizes your perception of belantamab mafodotin in combination (BVd, BPd) for the treatment of relapsed/refractory multiple myeloma?